|
 |
| home > news > detailed info |
|
|
 INDUSTRY NEWS AND PRESS RELEASES |
Sleep expert joins LCG Bioscience to build new facility |
LCG Bioscience |
|
"There are 89 recognised sleep disorders, and at any one time, around 30-35% of
the population suffer from the most common of these - insomnia," says Martin
King.
"There are many causes of insomnia and the medical and economic
consequences are well documented. However many sufferers simply accept their
symptoms, and try to mitigate the effects during periods of wakefulness by using
'alerting compounds' such as caffeine rather than seeking medical help to treat
the cause of their problems.
"Doctors and drug companies are realising
the importance of new safe, effective treatment for these people's heath and
wellbeing. The new LCG sleep laboratory will provide a dependable, proven
environment in which to test compounds that can help this neglected group of
sufferers."
Martin King, the former Head of the Sleep Laboratory at
PapworthHospital, has an extensive
knowledge of diagnosis and treatment of sleep disorders and has been actively
involved in professional sleep societies for many years. He has developed
techniques to accurately diagnose and quantify sleep disorders, and has seen
huge numbers of patients. He has participated in the development of
international measurement standards and has collaborated with researchers across
Europe and the USA.
The new facility at LCG
Bioscience will include sophisticated, state-of-the-art equipment that will be
used to monitor electrophysiology in order to accurately describe patterns of
sleep in both healthy volunteers and patients.
As well as investigating
treatments for the commonest sleep disorders, LCG will be able to draw on its
links with consultants such as neurologists to recruit patients from specific
disease groups for targeted clinical trials.
"Parkinson's disease
patients often suffer severe sleep disruption due to depression, the disease
process, and medication used to treat their symptoms," says Martin King. "LCG
already has strong relationships with practitioners in appropriate disciplines
to help enlist sufferers for trials. We also have the medical and nursing
experience to care for patients whilst delivering high quality
research.
"A number of drugs targeted at other medical conditions also
have profound effects on sleep. We have the potential in the new facility to
investigate these disturbances in a thorough, scientific way, and the experience
and expertise to deliver results on time.
"At present, most sleep studies
are conducted in mainland Europe and North
America. We hope that in launching this cutting-edge facility we
will be able to make the UK a world leader in the development
and evaluation of drugs used to improve sleep and daytime
functioning."
For more information about LCG Bioscience's expertise in
polysomnography, visit www.lcg-bioscience.com or call +44 (0)1954 717271
|
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
PFIZER PRESENTS OVERALL SURVIVAL DATA FOR SUTENT™ VERSUS INTERFERON-ALFA
Chicago, 31 May 2008- Results from a landmark study have shown that sunitinib (SUTENT™)
has demonstrated overall survival greater than two years in patients with
metastatic renal cell carcinoma (mRCC), also known as advanced kidney cancer.
This is the first time overall survival data representing more than two years
has been achieved in the first line setting of mRCC, which is clinically
meaningful and reflective of major advances in the treatment of kidney
cancer.
More info >> |
|
 |
Industry Events |
 |
Exploratory Clinical Development World Americas 2008
23-25 September 2008, Philadelphia Marriott Downtown, 1201 Market Street, Philadelphia, Pennsylvania, 19107 USA
Following on from the huge success of the Exploratory
Clinical Development World Europe, the Americas
congress will give you a critical insight into the latest strategies on how the
industry is addressing and elevating the current challenges in early clinical
development.
More info >> |
|
|
